New hope for Hard-to-Treat myeloma? early trial tests Two-Drug attack
NCT ID NCT05139225
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests a combination of two drugs—TTI-622 and daratumumab—in people whose multiple myeloma has returned or is not responding to treatment. The main goal is to find a safe dose of TTI-622 when given with daratumumab. Only 7 participants are enrolled, so the focus is on safety, not yet on how well the combo works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TTI-622 (a protein that blocks CD47) and daratumumab (a targeted antibody)
What this could lead to
If this combination proves safe and effective, it could offer a new treatment option for people with multiple myeloma that has returned or stopped responding to other therapies.
What could go wrong
This is a very early phase 1 trial with only 7 participants, so it is too small to prove effectiveness. The main goal is safety, and side effects or lack of benefit are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Commack
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Westchester
Harrison, New York, 10604, United States